Saquinavir

From WikiProjectMed
Jump to navigation Jump to search

Saquinavir
Saquinavir structure.svg
Saquinavir ball-and-stick.png
Names
Trade namesInvirase, Fortovase
Clinical data
Pregnancy
category
  • AU: B1[1]
  • US: B (No risk in non-human studies)[1]
Defined daily dose1.8 g[2]
External links
AHFS/Drugs.comMonograph
MedlinePlusa696001
Legal
License data
Legal status
Pharmacokinetics
Bioavailability~4% (without ritonavir boosting)[3]
Protein binding98%
MetabolismHepatic, mainly by CYP3A4
Elimination half-life9–15 hours
Excretionfeces (81%) and urine (3%)
Chemical and physical data
FormulaC38H50N6O5
Molar mass670.855 g·mol−1
3D model (JSmol)
  (verify)

Saquinavir (SQV), sold under the brand names Invirase and Fortovase, is an antiretroviral drug used together with other medications to treat or prevent HIV/AIDS.[4] Typically it is used with ritonavir or lopinavir/ritonavir to increase its effect.[4] It is taken by mouth.[4]

Common side effects include nausea, vomiting, diarrhea, and feeling tired.[4] More serious side effects include problems with QT prolongation, heart block, high blood lipids, and liver problems.[4] It appears to be safe in pregnancy.[4] It is in the protease inhibitor class and works by blocking the HIV protease.[4]

Saquinavir was patented in 1988 and first sold in 1995.[5][6] As of 2015 it is not available as a generic medication in the United States and is expensive.[7] The wholesale cost in the developing world is about 4.50 USD per day.[8]

Medical uses

Saquinavir is used together with other medications to treat or prevent HIV/AIDS.[4] Typically it is used with ritonavir or lopinavir/ritonavir to increase its effect.[4]

Dosage

The defined daily dose is 1.8 grams (by mouth).[2] The typical dose in adults is 1 gram, together with 100 mg of ritonavir, twice per day.[4]


The same dose is used in people with mild liver problems or kidney problems, though the medication is not recommended in those with severe liver problems.[4]

Side effects

The most frequent adverse events with saquinavir in either formulation are mild gastrointestinal symptoms, including diarrhoea, nausea, loose stools and abdominal discomfort. Invirase is better tolerated than Fortovase.[medical citation needed]

Bioavailability and drug interactions

Saquinavir, in the Invirase formulation, has a low and variable oral bioavailability, when given alone. The Fortovase formulation at the standard dosage delivers approximately eightfold more active drug than Invirase, also at the standard dosage.[9]

In the clinic, it was found that the oral bioavailability of saquinavir in both formulations significantly increases when patients also receive the PI ritonavir. For patients, this has the major benefit that they can take less saquinavir, while maintaining sufficient saquinavir blood plasma levels to efficiently suppress the replication of HIV.[medical citation needed]

The mechanism behind this welcome observation was not directly known, but later it was determined that ritonavir inhibits the cytochrome P450 3A4 isozyme. Normally, this enzyme metabolizes saquinavir to an inactive form, but with the ritonavir inhibiting this enzyme, the saquinavir blood plasma levels increased considerably. Additionally, ritonavir also inhibits multidrug transporters, although to a much lower extent.[medical citation needed]

Unlike other protease inhibitors, the absorption of saquinavir seems to be improved by omeprazole.[10]

Mechanism of action

Saquinavir is a protease inhibitor. Proteases are enzymes that cleave protein molecules into smaller fragments. HIV protease is vital for both viral replication within the cell and release of mature viral particles from an infected cell. Saquinavir binds to the active site of the viral protease and prevents cleavage of viral polyproteins, preventing maturation of the virus. Saquinavir inhibits both HIV-1 and HIV-2 proteases.[medical citation needed]

History

New HIV infections and deaths, before and after the FDA approval of "highly active antiretroviral therapy",[11] of which saquinavir, ritonavir and indinavir were key as the first three protease inhibitors.[citation needed] As a result of the new therapies, HIV deaths in the United States fell dramatically within two years.[11]

Saquinavir was developed by the pharmaceutical company Roche.[citation needed] Saquinavir was the sixth antiretroviral and the first protease inhibitor approved by the US Food and Drug Administration (FDA), leading ritonavir to approval by 4 months.[citation needed] As a result of the introduction of new "highly active antiretroviral thearap[ies]"—of which the protease inhibitors saquinavir and ritonavir were critical[citation needed]—the annual U.S. HIV-associated death rate fell from over 50,000 to about 18,000 over a period of two years.[11][12]

Roche requested and received approval of Invirase via the FDA's "Accelerated Approval" program—a process designed to speed drugs to market for the treatment of serious diseases—a decision that was controversial, as AIDS activists disagreed over the benefits of thorough testing versus early access to new drugs.[13][better source needed] It was approved again on November 7, 1997, as Fortovase,[14] a soft gel capsule reformulated for improved bioavailability. Roche announced in May 2005 that, given reduced demand, Fortovase would cease being marketed early in 2006, in favor of Invirase boosted with ritonavir,[15] owing to the ability of the latter co-formulated drug to inhibit the enzyme that metabolizes the AIDS drugs.[citation needed]

Society and culture

Cost

As of 2015, it is not available as a generic medication and is expensive.[7] The wholesale cost is about 4.50 USD per day.[8]

Formulations

Two formulations have been marketed:

  • a hard-gel capsule formulation of the mesylate, with trade name Invirase, which requires combination with ritonavir to increase the saquinavir bioavailability;
  • a soft-gel capsule formulation of saquinavir (microemulsion,[16] orally-administered formulation), with trade name Fortovase, which was discontinued worldwide in 2006.[17]

References

  1. 1.0 1.1 "Saquinavir Use During Pregnancy". Drugs.com. 20 March 2018. Retrieved 28 January 2020.
  2. 2.0 2.1 "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 22 September 2020.
  3. "Invirase- saquinavir mesylate capsule INVIRASE- saquinavir mesylate tablet, film coated". DailyMed. 26 December 2019. Retrieved 28 January 2020.
  4. 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 "Saquinavir". The American Society of Health-System Pharmacists. Archived from the original on 8 September 2015. Retrieved 5 September 2015.
  5. Minor, Lisa K. (2006). Handbook of Assay Development in Drug Discovery. Hoboken: CRC Press. p. 117. ISBN 9781420015706. Archived from the original on 31 March 2016.
  6. Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 509. ISBN 9783527607495.
  7. 7.0 7.1 Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 72. ISBN 9781284057560.
  8. 8.0 8.1 "Saquinavir". International Drug Price Indicator Guide. Retrieved 6 September 2015.
  9. "Fortovase". Drugs.com. 22 March 2019. Retrieved 28 January 2020.
  10. Winston A, Back D, Fletcher C, et al. (2006). "Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers". AIDS. 20 (10): 1401–6. doi:10.1097/01.aids.0000233573.41597.8a. PMID 16791014.
  11. 11.0 11.1 11.2 "HIV Surveillance—United States, 1981-2008". Archived from the original on 9 November 2013. Retrieved 8 November 2013.
  12. The CDC, in its Morbidity and Mortality Weekly Report, ascribes this to "highly active antiretroviral therapy", without mention of either of these drugs, see the preceding citation. A further citation is needed to make this accurate connection between this drop and the introduction of the protease inhibitors.
  13. "Drugs! Drugs! Drugs! An Overview of the Approved Anti-HIV Medications". The Body. Archived from the original on 9 November 2013. Retrieved 20 February 2013.
  14. "Drug Approval Package: Fortovase/Saquinavir NDA 20828". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 28 January 2020.
  15. Withdrawal of Fortovase (PDF) Archived 2006-05-14 at the Wayback Machine
  16. Gibaud S, Attivi D (August 2012). "Microemulsions for oral administration and their therapeutic applications" (PDF). Expert Opinion on Drug Delivery. 9 (8): 937–51. doi:10.1517/17425247.2012.694865. PMID 22663249.
  17. News-Medical.Net. May 18, 2005 Roche to discontinue the sale and distribution of Fortovase (saquinavir) Archived 2015-02-22 at the Wayback Machine

External links

External sites:
Identifiers: